BioLineRx Ltd. Receives Approval to Complete Phase 1/2 Clinical Trials of BL-1040, a Breakthrough Treatment for Acute Myocardial Infarction

JERUSALEM--(BUSINESS WIRE)--BioLineRx Ltd. (TASE:BLRX), a clinical stage drug development company, today announced that the Independent Safety Monitoring Board (ISMB) for the BL-1040 pilot study authorized the completion of the Phase 1/2 study and enrollment of the additional 25 patients. The ISMB's decision is based on safety assessments of the first 5 patients to complete at least 30 days of follow up following treatment with BL-1040 without noticeable adverse events. BL-1040 is a breakthrough treatment for preventing further heart damage following acute myocardial infarction (MI).

Back to news